The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution   Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)     Karim Chamie Consulting or Advisory Role - Johnson & Johnson/Janssen; Pfizer; Urogen pharma Speakers' Bureau - Johnson & Johnson/Janssen Research Funding - Urogen pharma Expert Testimony - GlaxoSmithKline   Marco Maruzzo Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Johnson & Johnson; Merck; MSD; Recordati Research Funding - Bristol-Myers Squibb (Inst); Johnson & Johnson (Inst); Merck (Inst); MSD (Inst); Roche (Inst)   Osvaldo Padron Consulting or Advisory Role - Boston Scientific; Neuspera Research Funding - Neuspera   Maria Ribal Honoraria - Bayer; Roche Patents, Royalties, Other Intellectual Property - INTELECTUAL PROPERTY NO ROYALTIES: METODO DE DIAGNOSTICO NO INVASIVO DE CANCER DE VEJIGA. Inventores: Antonio Alcaraz, Lourdes Mengual, María José Ribal, Juan José Lozano. Oficina de patente: European Patent Office. Número de concesión: 13382030.8-1403. E   Valentina Boni Employment - Director of Clinical Cancer Research, NEXT Madrid, Hospital Universitario QuirónSalud Pozuelo Stock and Other Ownership Interests - 1TRIALSP Honoraria - Gedefo; Getthi; IDMC Nanobiotix NANORAY-312/Novartis; Lilly; MSD; SOLTI; Steering Committee CytomX Therapeutics; TACTICS Consulting or Advisory Role - Affi med; Alentis Therapeutics; CytomX Therapeutics; EMD Serono; Guidepoint Pharmacy; IDEAYA Biosciences; Janssen; Lilly; Loxo Therapeutics; OncoArt; Puma Biotechnology Research Funding - Abbvie (Inst); ACEO (Inst); Adaptaimmune (Inst); Affi med (Inst); Amcure (Inst); Amgen (Inst); Amunix (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Boehringer Ingelheim (Inst); Boston Therapeutics (Inst); Bristol-Myers Squibb (Inst); Carrick Therapeutics (Inst); Constellation Pharmaceutical (Inst); Crescendo Biologics (Inst); Cullinan Oncology (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Dynavax Technologies (Inst); Ellipses Pharma (Inst); Exelesis (Inst); Famawav (Inst); Genentech/Roche (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Ideaya Bioscience (Inst); Incyte (Inst); Invox Pharma (Inst); iOMX Therapeutics (Inst); Ipsen (Inst); Janssen (Inst); Kronos Bio (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); MacroGenics (Inst); Menarini (Inst); Merck (Inst); Mersana (Inst); Merus (Inst); Millennium (Inst); Moderna Therapeutics (Inst); MSD (Inst); Nanobiotix (Inst); Navire (Inst); Nektar (Inst); Novartis (Inst); ORCA (Inst); Pfizer (Inst); PharmaMar (Inst); Principa Biopharma (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Ribbon (Inst); Ryvu Therapeutics (Inst); Salubris Biotherapeutics (Inst); Sanofi (Inst); Scorpion Therapeutics (Inst); Seagen (Inst); Seagen (Inst); Spectrum Pharmaceuticals (Inst); Stemline Therapeutics (Inst); Synthon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tesaro (Inst); Tolrelmo therapeutics (Inst); Totus Medicine (Inst); Transgene (Inst); Tyra Bioscience (Inst); UroGen pharma (Inst); Vividion Therapeutics (Inst); Xencor (Inst); Zai Biopharmaceutical (Inst); Zenith (Inst) Travel, Accommodations, Expenses - Bayer   Fabricio Racca Speakers' Bureau - KAM Merk Oncology Travel, Accommodations, Expenses - KAM Merk Oncology   Jonathan Henderson Consulting or Advisory Role - ImmunityBio; Johnson & Johnson; Pfizer/Astellas; UroGen pharma Speakers' Bureau - Johnson & Johnson/Janssen Research Funding - CG Oncology (Inst); Clarity Pharmaceuticals (Inst); enGene (Inst); Ferring (Inst); Johnson & Johnson/Janssen (Inst); Protara Therapeutics (Inst); Telix Pharmaceuticals (Inst); UroGen pharma (Inst)   Jay Raman Stock and Other Ownership Interests - United Medical Speakers' Bureau - Pacific Edge Research Funding - Pacific Edge; Steba Biotech; UroGen pharma   Jed Kaminetsky Research Funding - UroGen pharma (Inst)   Irene Moreno Consulting or Advisory Role - BOXER CAPITAL LLC; ELLIPSES PHARMA; Guidepoint Global Speakers' Bureau - Getthi group Research Funding - DIGICORE (IDEAL4RWE); FUNDACIÓN INTHEOS   Caretha Creasy Employment - UroGen pharma Stock and Other Ownership Interests - BioNTech; GlaxoSmithKline; Haleon; Moderna Therapeutics; UroGen pharma Patents, Royalties, Other Intellectual Property - UroGen pharma